Posaconazole - Merck & Co.

Drug Profile

Posaconazole - Merck & Co.

Alternative Names: IV posaconazole; MK-5592; Noxafil; Posaconazole oral suspension; Posaconazole SP; Posaconazole tablet; Posanol; SCH 056592; SCH 56592; Spriafil

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; MSD China; Schering-Plough
  • Class Antifungals; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidiasis; Mycoses; Oropharyngeal candidiasis
  • Phase II Chagas disease

Most Recent Events

  • 26 Jun 2018 Merck Sharp & Dohme completes a phase I trial in Mycoses (In adolescents, In children) in Denmark, Germany, Norway, Spain, Czech Republic, Belgium, Italy and Sweden (NCT02452034)
  • 24 Jun 2018 Biomarkers information updated
  • 24 Jan 2018 Merck completes a phase III trial in Aspergillosis in Japan (IV) (NCT02180165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top